US Stock Insider Trading | Xeris Biopharma disclosed two insider transactions on March 4

K-LinePoet · 2026-03-29T16:36:18+00:00

Xeris Biopharma disclosed an insider transaction where executive Hecht Beth sold 16,000 shares of stock on March 2, 2026. The company focuses on improving patients' lives through innovative biopharmaceuticals, with unique product and formulation science.

K-LinePoet

2026-03-29 16:36:18

Abstract generation in progress

On March 4, 2026, Xeris Biopharma (XERS) disclosed two transactions involving corporate insiders. Executive Hecht Beth sold 16,600 shares on March 2, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Shares	Trade Price per Share/US$	Total Value/US$
March 4, 2026	Executive	Hecht Beth	March 2, 2026	Sold	100	7.06	706.00
March 4, 2026	Executive	Hecht Beth	March 2, 2026	Sold	16,600	6.24	103,400
February 25, 2026	Executive	Nguyen Anh Tu	February 24, 2026	Sold	29,300	6.88	201,600
February 2, 2026	Executive	McCulloch Kevin	January 31, 2026	Sold	126,100	7.36	927,800
February 2, 2026	Executive	Pieper Steven	January 31, 2026	Sold	205,500	7.36	1,512,700
February 2, 2026	Executive	Hecht Beth	January 31, 2026	Sold	169,600	7.36	1,247,900
February 2, 2026	Executive	Hecht Beth	February 2, 2026	Sold	16,700	7.45	124,100
February 2, 2026	Director	Shannon John Patrick Jr	January 31, 2026	Sold	340,500	7.36	2,506,100
January 9, 2026	Executive	McCulloch Kevin	January 8, 2026	Sold	15,000	8.00	120,000
January 6, 2026	Director	Shannon John Patrick Jr	January 5, 2026	Purchased	2900	3.94	11,400

[Company Information]

Xeris Biopharma Holdings, Inc. was incorporated in 2005 under the laws of the State of Delaware. The company is committed to building an innovative, self-sustaining, growth-oriented biopharmaceutical company, dedicated to improving patients’ lives by developing and commercializing a range of clinically meaningful therapies. The company has a unique advantage in achieving this goal through three commercial products and proprietary formulation science (XeriSol and XeriJect), thereby establishing partnerships and strengthening candidate products.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes